Hydrogen Inhalation Therapy
In China, clinical trials (for public approval) on molecular hydrogen inhalation therapy as a means of treating COVID-19 began in Feb 2020. This test has been opened to the International Standard-based protocol and was also released in English (Registration no. CTR2000029739).
The chief doctor responsible for this test was Dr. Nan-shan Zhong, who had been appointed as the top chief of the “upper expert team” of the National Health and Health Commission of China.
Dr. Zhong published a study on the inhibition of severity and improvement of breathing difficulties of new COVID patients through hydrogen inhalation therapy. In addition, he argued that hydrogen inhalation therapy should be the standard treatment method for treating COVID patients.